| Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial S Horwitz, OA O'Connor, B Pro, T Illidge, M Fanale, R Advani, NL Bartlett, ... The Lancet 393 (10168), 229-240, 2019 | 764 | 2019 |
| Changing aetiology, clinical features, antimicrobial resistance, and outcomes of bloodstream infection in neutropenic cancer patients C Gudiol, M Bodro, A Simonetti, F Tubau, E González-Barca, M Cisnal, ... Clinical Microbiology and Infection 19 (5), 474-479, 2013 | 332 | 2013 |
| Nivolumab for newly diagnosed advanced-stage classic Hodgkin lymphoma: safety and efficacy in the phase II CheckMate 205 study R Ramchandren, E Domingo-Domènech, A Rueda, M Trněný, ... Journal of Clinical Oncology 37 (23), 1997-2007, 2019 | 245 | 2019 |
| The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma S Horwitz, OA O'Connor, B Pro, L Trümper, S Iyer, R Advani, NL Bartlett, ... Annals of Oncology 33 (3), 288-298, 2022 | 189 | 2022 |
| Gastrointestinal involvement in mantle cell lymphoma: a prospective clinic, endoscopic, and pathologic study A Salar, N Juanpere, B Bellosillo, E Domingo-Domenech, B Espinet, ... The American journal of surgical pathology 30 (10), 1274-1280, 2006 | 160 | 2006 |
| Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease E González Barca, E Domingo Domènech, FJ Capote, J Gómez Codina, ... Haematologica, 2007, vol. 92, num. 11, p. 1489-1494, 2007 | 152 | 2007 |
| Inappropriate empirical antibiotic treatment in high-risk neutropenic patients with bacteremia in the era of multidrug resistance G Martinez-Nadal, P Puerta-Alcalde, C Gudiol, C Cardozo, ... Clinical Infectious Diseases 70 (6), 1068-1074, 2020 | 147 | 2020 |
| Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group) R Garcia-Sanz, A Sureda, F de la Cruz, M Canales, AP Gonzalez, ... Annals of Oncology 30 (4), 612-620, 2019 | 130 | 2019 |
| A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma NL Bartlett, AF Herrera, E Domingo-Domenech, A Mehta, A Forero-Torres, ... Blood, The Journal of the American Society of Hematology 136 (21), 2401-2409, 2020 | 128 | 2020 |
| Combination therapy with rituximab and intravenous or oral fludarabine in the first‐line, systemic treatment of patients with extranodal marginal zone B‐cell lymphoma of the … A Salar, E Domingo‐Domenech, C Estany, MA Canales, F Gallardo, ... Cancer 115 (22), 5210-5217, 2009 | 107 | 2009 |
| Risk stratification for S plenic M arginal Z one L ymphoma based on haemoglobin concentration, platelet count, high lactate dehydrogenase level and extrahilar lymphadenopathy … C Montalbán, V Abraira, L Arcaini, E Domingo‐Domenech, ... British journal of haematology 159 (2), 164-171, 2012 | 105 | 2012 |
| Epidemiology, antibiotic therapy and outcomes of bacteremia caused by drug-resistant ESKAPE pathogens in cancer patients M Bodro, C Gudiol, C Garcia-Vidal, F Tubau, L Boix, ... Supportive Care in Cancer 22, 603-610, 2014 | 99 | 2014 |
| First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosa-associated lymphoid tissue lymphoma (MALT2008-01): a … A Salar, E Domingo-Domenech, C Panizo, C Nicolás, J Bargay, ... The Lancet Haematology 1 (3), e104-e111, 2014 | 96 | 2014 |
| Primary cutaneous marginal zone B-cell lymphoma: response to treatment and disease-free survival in a series of 137 patients O Servitje, C Muniesa, Y Benavente, V Monsálvez, MP Garcia-Muret, ... Journal of the American Academy of Dermatology 69 (3), 357-365, 2013 | 96 | 2013 |
| Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma A Salar, E Domingo-Domenech, C Panizo, C Nicolás, J Bargay, ... Blood, The Journal of the American Society of Hematology 130 (15), 1772-1774, 2017 | 93 | 2017 |
| Rheumatic immune-related adverse events in patients on anti-PD-1 inhibitors: fasciitis with myositis syndrome as a new complication of immunotherapy J Narváez, P Juarez-López, J LLuch, JA Narváez, R Palmero, ... Autoimmunity reviews 17 (10), 1040-1045, 2018 | 86 | 2018 |
| Lack of serological evidence for an association between simian virus 40 and lymphoma S De Sanjose, KV Shah, E Domingo‐Domenech, EA Engels, ... International journal of cancer 104 (4), 522-524, 2003 | 85 | 2003 |
| Factors influencing mortality in neutropenic patients with haematologic malignancies or solid tumours with bloodstream infection M Marín, C Gudiol, C Ardanuy, C Garcia-Vidal, L Jimenez, ... Clinical Microbiology and Infection 21 (6), 583-590, 2015 | 84 | 2015 |
| CD38 expression in B-chronic lymphocytic leukemia: association with clinical presentation and outcome in 155 patients E Domingo-Domènech, A Domingo-Clarós, E Gonzalez-Barca, ... Haematologica 87 (10), 1021-1027, 2002 | 84 | 2002 |
| CCR5 Δ32 homozygous cord blood allogeneic transplantation in a patient with HIV: a case report RF Duarte, M Salgado, I Sánchez-Ortega, M Arnan, C Canals, ... The Lancet HIV 2 (6), e236-e242, 2015 | 76 | 2015 |
